Ethan B Ludmir1, Sarah A Milgrom1, Chelsea C Pinnix1, Jillian R Gunther1, Jason Westin2, Luis E Fayad2, Joseph D Khoury3, L Jeffrey Medeiros3, Bouthaina S Dabaja1, Loretta J Nastoupil4. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: lnastoupil@mdanderson.org.
Abstract
INTRODUCTION: We report our experience in treating patients with primary breast extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) to better elucidate the natural history and optimal treatment approach for these patients. PATIENTS AND METHODS: Patients with localized primary breast MALT lymphoma treated between 1995 and 2016 were included. Disease-related endpoints including progression-free survival (PFS) were analyzed. RESULTS: Eleven patients met inclusion criteria; all patients were women with a median age of 62 years (range, 42-75 years). Most (73%) patients presented with stage I disease, and most (73%) patients were treated initially treated with radiation therapy (RT). Local control following RT was 100%; all patients with progression following RT experienced distant relapse. Additionally, none of the 3 patients treated with ultra-low-dose RT (4 Gy) experienced subsequent progression (local or distant). Six (55%) patients progressed after initial therapy, of whom 5 received initial RT; the 5-year PFS after initial therapy was 60%. Salvage systemic therapy was utilized in all patients with progression, with 5 of 6 patients receiving single-agent rituximab. Of the patients treated with salvage therapy, only 1 experienced second relapse, with a 5-year PFS of 100% after salvage systemic therapy. With a median follow-up of 8 years, there were no deaths in the cohort. CONCLUSIONS: Patients with primary breast MALT lymphoma achieve excellent outcomes. Initial RT affords local control, and although subsequent distant progression is common, salvage rituximab yields high rates of PFS.
INTRODUCTION: We report our experience in treating patients with primary breast extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) to better elucidate the natural history and optimal treatment approach for these patients. PATIENTS AND METHODS: Patients with localized primary breast MALT lymphoma treated between 1995 and 2016 were included. Disease-related endpoints including progression-free survival (PFS) were analyzed. RESULTS: Eleven patients met inclusion criteria; all patients were women with a median age of 62 years (range, 42-75 years). Most (73%) patients presented with stage I disease, and most (73%) patients were treated initially treated with radiation therapy (RT). Local control following RT was 100%; all patients with progression following RT experienced distant relapse. Additionally, none of the 3 patients treated with ultra-low-dose RT (4 Gy) experienced subsequent progression (local or distant). Six (55%) patients progressed after initial therapy, of whom 5 received initial RT; the 5-year PFS after initial therapy was 60%. Salvage systemic therapy was utilized in all patients with progression, with 5 of 6 patients receiving single-agent rituximab. Of the patients treated with salvage therapy, only 1 experienced second relapse, with a 5-year PFS of 100% after salvage systemic therapy. With a median follow-up of 8 years, there were no deaths in the cohort. CONCLUSIONS:Patients with primary breast MALT lymphoma achieve excellent outcomes. Initial RT affords local control, and although subsequent distant progression is common, salvage rituximab yields high rates of PFS.
Authors: Hailing Liu; Jing Zhang; Lin Quan; Lei Cao; Yi Miao; Xiaoli Zhao; Haorui Shen; Li Wang; Wei Xu; Jianyong Li; Lei Fan Journal: Front Oncol Date: 2021-04-13 Impact factor: 6.244
Authors: Cecile D Moliva Anendaga; Madhavi Raghu; Jaime L Szarmach; Seema Bakhru; Francis T Flaherty; Gilda Boroumand Journal: Radiol Case Rep Date: 2022-08-20
Authors: Marzia Cerrato; Erika Orlandi; Angelisa Vella; Sara Bartoncini; Giuseppe C Iorio; Diego Bongiovanni; Francesco Capriotti; Carola Boccomini; Francesco Vassallo; Chiara Cavallin; Viola De Luca; Francesca R Giglioli; Umberto Ricardi; Mario Levis Journal: Br J Radiol Date: 2021-06-16 Impact factor: 3.039